Dr. Calzolai obtained his M.S. in chemistry and his Ph.D. in chemistry from the University of Florence and the University of Sienna, respectively.
After a Postgraduate Research at the University of California, Davis, he joined, in 1998, the Swiss Institute of Technology in Zurich, in the laboratory of the then Nobel laureate Kurth Wuthrich, where he determined the three dimensional structure of prion proteins responsible of neurological disorders, such as Mad Cow Disease and Creutzfeld-Jacob disease.
In 2007 he moved to the School of Pharmacy of the University of Kent (UK) as Senior Lecturer in biochemistry.
In 2008 he joined the Joint Research Center of the European Commission where his research focuses on the development of methods for the detection and characterization of nanoparticles, nanomedicines, and biotherapeutics.
He was a member of the Core Expert Team of the European Union Nanomedicine Characterization Laboratory (EUNCL).
He is coordinating the JRC participation to the H2020 project ATAC (Antibody therapy against coronavirus - COVID-2019) and to the Research Infrastructure for Pandemic Preparedness (ISIDORE).